Alpralid

/ CTS

In adults: For treatment of anxiety: The treatment will usually begin with one tablet of 0.25 mg or one tablet of 0.5 mg three times per day. Therefore, the daily dosage is 0.75 mg to 1.5 mg. The dosage may be gradually increased (every 3-4 days the dose may be increased by 1 mg) up to a total daily dosage of 3 mg, divided throughout the day.
The dosage can be increased to achieve a maximum therapeutic effect, at intervals of 3 to 4 days, to a maximum daily dosage
of 4 mg, given in divided doses.
For treatment of panic: The treatment will usually begin with one tablet of 0.5 mg three times per day. The dosage can be
gradually increased, depending on the response, (every 3-4 days the dose can be increased by 1 mg) up to a daily dosage greater than 4 mg, divided throughout the day. When the dosage needs to be increased, the common practice is to increase the nighttime
dosage first before increasing the daytime dosage, to make sure you will remain alert during the day. If you start feeling side
effects, the doctor may reduce your dosage.
The elderly or patients suffering from a disease that causes fatigue: The accepted starting dosage is 0.25 mg twice to three times per day. This dosage may be gradually increased, according to the doctor’s instructions, if necessary and if you do not suffer from any side effects. Do not exceed the recommended dose.
Duration of treatment Alpralid is intended for short-term use (no
more than 8-12 weeks). Usually, the doctor will assess your
condition at the latest by the end of 4 weeks, and decide if further treatment is required.
In some cases, according to the assessment of a specialist, there may be a need to extend treatment beyond the maximum treatment period. The effect of the medicine may be reduced if it is used for more than a few weeks.
Method of administration
Do not chew! The tablet is intended to be swallowed. If necessary, the tablet can be halved or crushed

Anxiety, tension, including associated with depression, panic disorders with/without association with phobia.

Hypersensitivity to the active substance or any of its excipients.
Hypersensitivity to other benzodiazepines
Concomittant use with antifungals e.g. Ketoconazole,
Itraconazole.

Please refer to license holder for full details.

Please refer to license holder for full details.

Please refer to license holder for full details.

Please refer to license holder for full details.

Please refer to license holder for full details.

Please refer to license holder for full details.